Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleInflammation, Immunopharmacology, and Asthma

Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP

Rakesh K. Singh, Leon van Haandel, Daniel P. Heruth, Shui Q. Ye, J. Steven Leeder, Mara L. Becker and Ryan S. Funk
Journal of Pharmacology and Experimental Therapeutics April 2018, 365 (1) 96-106; DOI: https://doi.org/10.1124/jpet.117.246199
Rakesh K. Singh
Departments of Pharmacy Practice (R.K.S., R.S.F.) and Pharmacology, Toxicology, and Therapeutics (J.S.L., R.S.F.), University of Kansas Medical Center, Kansas City, Kansas; Divisions of Clinical Pharmacology, Toxicology and Therapeutic Innovation (L.v.H., J.S.L., M.L.B.), Rheumatology (M.L.B.), and Experimental and Translational Genetics (D.P.H., S.Q.Y.), Children’s Mercy Kansas City, Kansas City, Missouri; and Department of Biomedical and Health Informatics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri (S.Q.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leon van Haandel
Departments of Pharmacy Practice (R.K.S., R.S.F.) and Pharmacology, Toxicology, and Therapeutics (J.S.L., R.S.F.), University of Kansas Medical Center, Kansas City, Kansas; Divisions of Clinical Pharmacology, Toxicology and Therapeutic Innovation (L.v.H., J.S.L., M.L.B.), Rheumatology (M.L.B.), and Experimental and Translational Genetics (D.P.H., S.Q.Y.), Children’s Mercy Kansas City, Kansas City, Missouri; and Department of Biomedical and Health Informatics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri (S.Q.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel P. Heruth
Departments of Pharmacy Practice (R.K.S., R.S.F.) and Pharmacology, Toxicology, and Therapeutics (J.S.L., R.S.F.), University of Kansas Medical Center, Kansas City, Kansas; Divisions of Clinical Pharmacology, Toxicology and Therapeutic Innovation (L.v.H., J.S.L., M.L.B.), Rheumatology (M.L.B.), and Experimental and Translational Genetics (D.P.H., S.Q.Y.), Children’s Mercy Kansas City, Kansas City, Missouri; and Department of Biomedical and Health Informatics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri (S.Q.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shui Q. Ye
Departments of Pharmacy Practice (R.K.S., R.S.F.) and Pharmacology, Toxicology, and Therapeutics (J.S.L., R.S.F.), University of Kansas Medical Center, Kansas City, Kansas; Divisions of Clinical Pharmacology, Toxicology and Therapeutic Innovation (L.v.H., J.S.L., M.L.B.), Rheumatology (M.L.B.), and Experimental and Translational Genetics (D.P.H., S.Q.Y.), Children’s Mercy Kansas City, Kansas City, Missouri; and Department of Biomedical and Health Informatics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri (S.Q.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Steven Leeder
Departments of Pharmacy Practice (R.K.S., R.S.F.) and Pharmacology, Toxicology, and Therapeutics (J.S.L., R.S.F.), University of Kansas Medical Center, Kansas City, Kansas; Divisions of Clinical Pharmacology, Toxicology and Therapeutic Innovation (L.v.H., J.S.L., M.L.B.), Rheumatology (M.L.B.), and Experimental and Translational Genetics (D.P.H., S.Q.Y.), Children’s Mercy Kansas City, Kansas City, Missouri; and Department of Biomedical and Health Informatics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri (S.Q.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mara L. Becker
Departments of Pharmacy Practice (R.K.S., R.S.F.) and Pharmacology, Toxicology, and Therapeutics (J.S.L., R.S.F.), University of Kansas Medical Center, Kansas City, Kansas; Divisions of Clinical Pharmacology, Toxicology and Therapeutic Innovation (L.v.H., J.S.L., M.L.B.), Rheumatology (M.L.B.), and Experimental and Translational Genetics (D.P.H., S.Q.Y.), Children’s Mercy Kansas City, Kansas City, Missouri; and Department of Biomedical and Health Informatics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri (S.Q.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryan S. Funk
Departments of Pharmacy Practice (R.K.S., R.S.F.) and Pharmacology, Toxicology, and Therapeutics (J.S.L., R.S.F.), University of Kansas Medical Center, Kansas City, Kansas; Divisions of Clinical Pharmacology, Toxicology and Therapeutic Innovation (L.v.H., J.S.L., M.L.B.), Rheumatology (M.L.B.), and Experimental and Translational Genetics (D.P.H., S.Q.Y.), Children’s Mercy Kansas City, Kansas City, Missouri; and Department of Biomedical and Health Informatics, University of Missouri Kansas City School of Medicine, Kansas City, Missouri (S.Q.Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Figures & Data

Figures

  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    Inhibition of NAMPT sensitizes primary human tissue to the growth inhibitory effects of MTX. Primary human fibroblasts were transfected with either control scrambled siRNA or with NAMPT-specific siRNA. (A) Twenty-four hours after transfection, cells were treated with MTX at concentrations up to 10 µM for 96 hours. (B) Isolated human lymphocytes were left unstimulated or were stimulated with 2% phytohemagglutinin and treated with either 10 nM MTX alone, 0.1 nM FK-866 alone, or 10 nM MTX in combination with 0.1 nM FK-866. Cell viability was measured by fluorescence spectroscopy using the resazurin reduction assay. Experiments were conducted in triplicate and the resulting mean ± S.D. for each experiment is presented. Statistical testing was conducted using t test analysis. Scr, scrambled.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    MTX activity in NAMPT-deficient cells is folate dependent. A549 cells were transfected with either control scrambled siRNA or with siRNA directed toward NAMPT. Twenty-four hours after transfection, cells were treated with different concentrations of MTX alone or in combination with 10 μM folinic acid for 96 hours. (A–C) Knockdown of NAMPT by siRNA was confirmed by Western blot analysis (A), quantified by densitometry analysis (B), and verified by real-time-PCR (C). Cell viability was measured by fluorescence spectroscopy using the resazurin reduction assay. (D) The effect of MTX toxicity alone or in combination with 10 μM folinic acid was determined as percent viability based on untreated control cells. Experiments were conducted in triplicate and the resulting mean ± S.D. for each experiment is presented. Concentrations of MTX required for half-maximal inhibition of 50% inhibition of cell viability were determined and compared by t test analysis. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MW, molecular weight; Scr, scrambled.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    NAD supplementation reverses enhanced MTX sensitivity in NAMPT-deficient cells. (A) A549 cells were transfected with either control scrambled siRNA or with siRNA directed toward NAMPT and cellular NAD levels were measured 96 hours after transfection. (B) Cellular viability was measured in NAMPT-deficient cells and treated with various concentrations of MTX with or without supplementation of 200 μM NAD. Experiments were conducted in triplicate and the resulting mean ± S.D. for each experiment is presented. NAD levels were compared by t test analysis. Concentrations of MTX required for half-maximal inhibition of 50% inhibition of cell viability were determined and compared by t test analysis. Scr, scrambled.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Inhibition of NAMPT does not affect DHFR expression or intracellular levels of folate or MTX. (A) A549 cells were transfected with either control scrambled siRNA or with siRNA directed toward NAMPT and protein levels of DHFR were monitored 96 hours after transfection. (B) For densitometry analysis, DHFR protein levels were normalized to GAPDH. (C and D) Cellular concentrations of folate (C) and MTX levels (D) were analyzed in control and NAMPT-deficient cells treated for 24 hours with 1000 nM MTX. Experiments were conducted in triplicate and the resulting mean ± S.D. for each experiment is presented and compared by t test analysis. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, not significant; Scr, scrambled.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    MTX does not cause synergistic depletion of cellular NAD in NAMPT-deficient cells. (A) A549 cells were transfected with either control scrambled siRNA or with siRNA directed toward NAMPT; 24 hours after transfection, cells were treated with 1000 nM MTX for 96 hours or 50 mM etoposide for 24 hours to determine activation of PARP by measuring PAR formation by Western blot analysis. (B) Control and NAMPT-deficient cells were treated with different concentrations of MTX for 96 hours and total DNA was separated on 1% agarose gel to evaluate DNA damage. (C) Total NAD levels were monitored in control and NAMPT-deficient cells treated with different concentrations of MTX for 96 hours. Experiments were conducted in triplicate and the resulting mean ± S.D. for each experiment is presented and compared by t test analysis. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MW, molecular weight; NS, not significant; PAR, poly(ADP-ribose); Scr, scrambled.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Increased MTX activity does not occur through activation of PARP. A549 cells transfected with either control scrambled siRNA or with siRNA directed toward NAMPT were treated with different concentrations of MTX with or without 10 μM olaparib. (A and B) The effect of inhibition of PARP-1 by olaparib on MTX toxicity in control (A) and NAMPT-deficient (B) cells was determined by normalizing cell growth inhibition with MTX against control cells. Experiments were conducted in triplicate and the resulting mean ± S.D. for each experiment is presented. Concentrations of MTX required for half-maximal inhibition of 50% inhibition of cell viability were determined and compared by t test analysis. Scr, scrambled.

  • Fig. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 7.

    NAMPT inhibition results in the synergistic depletion of cellular ATP by MTX. (A and B) A549 cells transfected with either control scrambled siRNA or with siRNA directed toward NAMPT were treated with different concentrations of MTX and cellular ATP levels were measured 96 hours after transfection (A) and in response to treatment with different concentrations of MTX over 96 hours (B). The effect of MTX on cellular ATP was determined by normalizing cellular ATP levels to the untreated control cells. Experiments were conducted in triplicate and the resulting mean ± S.D. for each experiment is presented and compared by t test analysis. Scr, scrambled.

  • Fig. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 8.

    NAMPT inhibition does not affect AICART activity but is associated with an increase in intracellular intermediates of de novo purine biosynthesis. A549 cells were transfected with either control scrambled siRNA or with NAMPT-specific siRNA. (A–C) After 72 hours under normal culture conditions, cells were subsequently harvested and intracellular concentrations of ZMP (A) and IMP (B) and the ratio of IMP/ZMP (C) were determined. Experiments were conducted in triplicate and the resulting mean ± S.D. for each experiment is presented and compared by t test analysis. NS, not significant; Scr, scrambled.

  • Fig. 9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 9.

    Supplementation of nucleotide biosynthesis rescues cell viability and ATP levels, but not NAD levels. (A–C) A549 cells transfected with either control scrambled siRNA or with siRNA directed toward NAMPT were treated with 1000 nM MTX alone or together with a combination of 100 μM hypoxanthine and 100 μM thymidine for 96 hours and measured for cellular viability (A), cellular NAD levels (B), and cellular ATP levels (C). Experiments were conducted in triplicate and the resulting mean ± S.D. for each experiment is presented and compared by t test analysis. NS, not significant; Scr, scrambled.

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 365 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 365, Issue 1
1 Apr 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Nicotinamide Phosphoribosyltransferase Deficiency Potentiates the Antiproliferative Activity of Methotrexate through Enhanced Depletion of Intracellular ATP
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleInflammation, Immunopharmacology, and Asthma

NAMPT Deficiency Potentiates ATP Depletion by Methotrexate

Rakesh K. Singh, Leon van Haandel, Daniel P. Heruth, Shui Q. Ye, J. Steven Leeder, Mara L. Becker and Ryan S. Funk
Journal of Pharmacology and Experimental Therapeutics April 1, 2018, 365 (1) 96-106; DOI: https://doi.org/10.1124/jpet.117.246199

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleInflammation, Immunopharmacology, and Asthma

NAMPT Deficiency Potentiates ATP Depletion by Methotrexate

Rakesh K. Singh, Leon van Haandel, Daniel P. Heruth, Shui Q. Ye, J. Steven Leeder, Mara L. Becker and Ryan S. Funk
Journal of Pharmacology and Experimental Therapeutics April 1, 2018, 365 (1) 96-106; DOI: https://doi.org/10.1124/jpet.117.246199
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Pegylated UCN1 Improves Autoimmune disease
  • PK/PD of PDE Inhibitors in Autoimmune Hepatitis
  • Immunopharmacologic Assessment of KPL-404, a CD40 Antagonist
Show more Inflammation, Immunopharmacology, and Asthma

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics